Demis Hassabis on Isomorphic’s $600 million raise, AI, and healthcare’s future
Demis Hassabis, cofounder of DeepMind and 2024 Nobel Laureate, talks to Fortune about his AI drug discovery startup, ...
Endpoints News1d
Q&A: Demis Has­s­abis talks 'tur­bocharg­ing' Iso­mor­phic with $600M, ex­pand­ing in­to an­ti­bod­ies and the US
Isomorphic Labs CEO Demis Hassabis discusses $600M funding round, plans for a US office, and expanding into ...
Google DeepMind CEO says his passion for chess led to his career in AI
Demis Hassabis, a childhood chess prodigy, said his experience with the game afforded him his first brush with AI. He was ...
Alphabet’s AI drug discovery platform Isomorphic Labs raises $600M from Thrive
Isomorphic Labs, the AI drug-discovery platform that was spun out of Google's DeepMind in 2021, has raised external capital ...
University of Cambridge9d
Nobel laureate and Cambridge alumnus Sir Demis Hassabis heralds a new era of 'digital speed' drug discovery
Demis, who was last year jointly awarded the Nobel Prize in Chemistry with Google DeepMind colleague Dr John Jumper for their ...
Fierce Biotech3d
Alphabet's AI biotech Isomorphic Labs hauls in $600M to power next-gen drug design model
AI drug discovery firm Isomorphic Labs has completed the company’s first external funding round since its 2021 founding ...
Explore more
朝日新聞社3d
Nobel-winning AI developer says risks must also be assessed
This year’s Nobel Prizes were a “watershed moment” for artificial intelligence, according to Demis Hassabis, a co-winner of this year’s prize in chemistry. Hassabis, 48, CEO and co-founder ...